RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:543

Burkitt lymphoma

low confidenceDisorder

Also known as: Small non-cleaved cell lymphoma

Publications

33,441

Trials

223

Interventional, condition-specific

Researchers

1,234

Distinct authors in sample

Gene link

MYC

No Known Disease Relationship

Readiness

6/6

Stages with a signal

Clinical definition (Orphanet)

Burkitt lymphoma is a rare form of malignant mature B-cell non-Hodgkin lymphoma.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (7)

Burkitt lymphoma/leukemia · Burkitt's lymphoma · Burkitt's tumour · Burkitt's tumour or lymphoma · burkitt lymphoma, somatic · small non-cleaved cell lymphoma · small non-cleaved cell lymphoma, Burkitt's type

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

6/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPartial

    No Known Disease Relationship — MYC

  2. LiteraturePresent

    33,441 matched papers (11,394 in last 10 years) Source

  3. Phenotype characterisedPresent

    16 HPO annotations (e.g. Abnormality of the pancreas; Abnormality of the spleen; Nausea and vomiting) Source

  4. Animal modelPresent

    6 genotype models (Mus musculus) Source

  5. Orphan designationPresent

    1 FDA · 1 EMA designations (1 FDA orphan-indication approval) — e.g. 6,8-bis(benzylthio)octanoic acid Source

  6. Interventional trialPresent

    223 matched on ClinicalTrials.gov (24 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

16

Associated phenotypes · MONDO:0007243

  • Abnormality of the pancreas
  • Abnormality of the spleen
  • Nausea and vomiting
  • Abdominal pain
  • Abnormal lymph node morphology

Showing 5 of 16 — open Monarch for the full list.

Animal models (Monarch / Alliance)

6

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

2

Designations · 1 with FDA orphan-indication approval

  • FDA 6,8-bis(benzylthio)octanoic acidBurkitts Lymphoma · 2018-01-25 · Not FDA Approved for Orphan Indication
  • EMA DevimistatTreatment of Burkitt's lymphoma · 15/10/2021 · PositiveEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

58

Drugs / clinical candidates · MONDO_0007243

CTD chemicals (MyDisease.info)

23 associated chemicals · 302 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • AIEOP acute lymphoblastic leukemia protocol · therapeutic
  • Arsenic Trioxide · therapeutic
  • Artesunate · therapeutic
  • BFM-86 protocol · therapeutic
  • BFM-ALL 81 protocol · therapeutic
  • COP protocol 2 · therapeutic
  • Cyclophosphamide · therapeutic
  • Cytarabine · therapeutic
  • Daunorubicin · therapeutic
  • DAV regimen · therapeutic
  • Dexamethasone · therapeutic
  • Doxorubicin · therapeutic

Pathways: Citrate cycle (TCA cycle); Histidine metabolism; Glycosphingolipid biosynthesis - lacto and neolacto series; Glycosphingolipid biosynthesis - globo and isoglobo series; Pyruvate metabolism; One carbon pool by folate; Metabolic pathways; Carbon metabolism

MyDisease.info · MONDO:0007243

Literature

Is anyone studying this?

33,441

33,441 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

33,441 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

11,394 in the last 10 years · low confidence

Phrase hits: 33,441 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,234

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Liu Y6 papers · 2026

    Department of Hematology Oncology Chongqing University Cancer Hospital Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing China.

    Papers in Europe PMC
  2. 02
    Mbulaiteye SM6 papers · 2026

    National Cancer Institute, Bethesda, MD, USA.

    Papers in Europe PMC
  3. 03
    Zhang Y6 papers · 2025

    Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, Key Laboratory of Major Disease in Children, Ministry of Education, Beijing, 100045, China.

    Papers in Europe PMC
  4. 04
    Chen Y5 papers · 2025

    Dazhou Vocational and Technical College, Dazhou, Sichuan, China.

    Papers in Europe PMC
  5. 05
    Moormann AM5 papers · 2026

    Division of Immunology and Infectious Diseases, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. ann.moormann@umassmed.edu.

    Papers in Europe PMC
  6. 06
    Bailey JA4 papers · 2026

    Department of Pathology & Laboratory Medicine, Brown University, Providence, RI, USA.

    Papers in Europe PMC
  7. 07
    Jiang J4 papers · 2026

    Department of Radiology, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Yunnan Cancer Centre, Kunming, China.

    Papers in Europe PMC
  8. 08
    Li J4 papers · 2026

    Department of Hematology Oncology Chongqing University Cancer Hospital Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing China.

    Papers in Europe PMC
  9. 09
    Wang X4 papers · 2026

    Department of Gynecology, Beijing University First Hospital Ningxia Women's and Children's Hospital, Ningxia, China.

    Papers in Europe PMC
  10. 10
    Yan J4 papers · 2024

    Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, the Second Hospital of Dalian Medical University, Dalian 116027, China; Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian 116027, China; Department of Pediatric, Pediatric Oncology and Hematology Center, the Second Hospital of Dalian Medical University, Dalian 116027, China. Electronic address: yanjsdmu@dmu.edu.cn.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

223

interventional trials for this specific condition

223 interventional trials matched this specific condition name; 24 currently recruiting in our sample.

Data as of 11 September 2026

223 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.4th percentile).

low confidence · 99.4th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

223 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

16 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 20 · after dedupe 19 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 19 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (19)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Burkitt lymphoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Burkitt lymphoma" OR "Small non-cleaved cell lymphoma" OR "Burkitt lymphoma/leukemia" OR "Burkitt's lymphoma" OR "Burkitt's tumour" OR "Burkitt's tumour or lymphoma" OR "burkitt lymphoma, somatic" OR "small non-cleaved cell lymphoma, Burkitt's type"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Burkitt lymphoma" OR "Small non-cleaved cell lymphoma" OR "Burkitt lymphoma/leukemia" OR "Burkitt's lymphoma" OR "Burkitt's tumour" OR "Burkitt's tumour or lymphoma" OR "burkitt lymphoma, somatic" OR "small non-cleaved cell lymphoma, Burkitt's type"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 223 interventional · 16 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (33441) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T14:16:05.946Z